Avai BioAVAI -3.77%24 1-Year ROIIC % is 109.64 as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,713 Software companies, Avai Bio ranks better than 86.33% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Avai Bio's 1-Year ROIIC % for the quarter that ended in Dec. 2025 was 109.64%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Avai Bio's 1-Year ROIIC % or its related term are showing as below:
AVAI's 1-Year ROIIC % is ranked better than 86.33% of 2713
companies
in the Software industry
Industry Median: 4.27
vs AVAI: 109.64
Avai Bio (OTCPK:AVAI) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Avai Bio 1-Year ROIIC % Related Terms
Avai Bio 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Avai Bio's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Application subindustry, Avai Bio's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio 1-Year ROIIC % vs Software Industry
For the Software industry and Technology sector, Avai Bio's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Avai Bio's 1-Year ROIIC % falls into.
Avai Bio's 1-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -1.031 (Dec. 2025) - -1.895 (Dec. 2024) )
/
( 1.68 (Dec. 2025) - 0.892 (Dec. 2024) )
=
0.864
/
0.788
=
109.64%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Avai Bio (AVAI) has a 1-Year ROIIC % of 109.64 as of Dec. 2025. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #371 out of 2713 companies in the Software industry, placing it in the top 13.7%.
Is Avai Bio's 1-Year ROIIC % too high?
Avai Bio's current 1-Year ROIIC % is 109.64. The Software industry median 1-Year ROIIC % is 4.27. Avai Bio's value of 109.64 is 2467.7% above this industry median. Based on the distribution chart, Avai Bio ranks #371 out of 2713 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's 1-Year ROIIC % compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #371 out of 2713 companies for 1-Year ROIIC %. This places Avai Bio in the top 14% of its industry — outperforming the majority of peers. The industry median 1-Year ROIIC % is 4.27. Avai Bio's value of 109.64 is 2467.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Software company?
The median 1-Year ROIIC % among Software companies is 4.27, based on 2,713 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avai Bio's current 1-Year ROIIC % of 109.64 is 2467.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Avai Bio and its competitors. For the Software industry, the median 1-Year ROIIC % is 4.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current 1-Year ROIIC % is 109.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current 1-Year ROIIC % of 109.64. The current 1-Year ROIIC % is 109.64 and 2467.7% above the Software industry median of 4.27. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Avai Bio (AVAI), the current 1-Year ROIIC % is 109.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
